Geneseeq’s CanScan® test demonstrated 93 percent early-stage detection and a 98 percent specificity rate in a 3,700-person cohort
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.
